INDEX

anti-competitive practices, 78, 84, 105, 114, 237–238, 254, 261, 312, 337
arbitration, 35, 165, 187, 307, 315, 321–326, 338–339, 343–345, 360
Article 13 TRIPS
  societal objectives, 228
  user's rights, 228, 231
Article 27(3)b TRIPS
  patentability, 148
Article 30 TRIPS
  three-step test, 217, 219, 226
Article 31 TRIPS
  adequate remuneration, 233, 235–244, 253
Article 31*bis* TRIPS
  domination, 244, 249–250, 253, 255
  general functioning, 245
  manufacturing capacity, 244, 248–258
Article 66.2 TRIPS, xix, 75, 79, 262–273
Article 67 TRIPS, 15, 68, 116, 252, 262–263, 266, 276–280, 310
Article 7 TRIPS, *see also social and economic welfare*, *see also balance of rights and obligations*
  dissemination of technology, 71–72, 76, 78–79, 90, 199, 302, 341–342
  functions, 65–71
  instrumental justification, 89–92, 124
  mutual advantage, 12, 19–22, 25, 71, 80–81, 93, 100–102, 119–120, 139–140, 146, 198, 356
  promotion of technological innovation, 71, 76–79, 90, 199
  transfer of technology, 72, 77
Article 8 TRIPS
  competence-giving norm, 115, 117
  consistency test, 107, 109–110, 114, 116
  functions, 65–71
  national autonomy, 12, 117–120, 184, 197
  necessity test, 107–109, 114
Australia – Plain Packaging, xiii, 28, 66, 70–72, 86, 213–214

balance of rights and obligations, 25, 71–72, 80–85, 93, 101–102, 105, 110, 114, 118–120, 169, 198, 356–357
Berne Convention, xvi, 23, 73, 89, 151–153, 188, 202, 213, 289–290
BITs, *see also regime shifting*
  procedural quality, 350
  safeguarding clauses, 342
Bolar exception, 226–227
border enforcement measures, 334
Brazil – Measures Affecting Patent Protection, xv

Canada – Patent Protection of Pharmaceutical Products, xiii
capability approach, 11, 50, 53–57, 96, 201–202, 313
ceiling, 300–301, 307, 321
China – Audiovisual Products, xiv
China – Intellectual Property Rights, xiv, 23
climate change, *see also compulsory licenses, see also environmentally sound technologies (ESTs)*
  broad interpretation of health, 255
competition law, 115, 119, 235, 254

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 14 Nov 2026 at 09:40:10, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009743174.011

compulsory licences, *see also environmentally sound technologies (ESTs)*
adequate remuneration, 233–245, 253
grounds, 233–235, 252, 256–258, 312, 337
public non-commercial use, 234, 239
conflict of norms, 27, 121
copyright, 5, 150–155, 188, 213, 228, 230, 290–304

dispute settlements understanding (DSU), 27, 32, 324–326, 331–332
dissemination of technology, *See Article 7*
Doha Declaration, *see also Article 8 TRIPS*, *see also public health*
legal status, 112–114
domination, *See freedom as non-domination*
drugs
essential drugs, 116, 144–146, 242
price, 143, 145, 242, 246

EC – Hormones, xiv, 22, 24, 209–210, 219
EC – Trademark/GI, xiv
Eli Lilly v. *Canada*, xiii, 315, 325
environmentally sound technologies (ESTs), 95, 227, 233, 244, 256–261, 265
exceptions and limitations, *see also Article 30 TRIPS*, *see also Article 13 TRIPS*, *see also three-step test*
copyright, 5, 16, 217
functional approach, 206, 208, 211
mandatory, 16
mandatory exceptions, 212, 289
patent, 5

farmers' rights, 2, 148
flexibilities
definition, 14, 113–114, 205
interpretation of, 205
reinforcement in FTAs and BITs, 346
TRIPS-plus norms, 306, 308–314, 319, 337
forum shopping, 16, 259, 321–325
foundational norms
definition, 19
TRIPS foundations, 11, 17–18, 25, 57–58, 120, 128, 138, 198, 204, 210, 282, 295, 305, 328, 338
framing
concept, 61
functions, 62
free trade agreements (FTAs), 2, 5, 67
consistency with TRIPS, 327, 331, 333, 338, 343, 346
inter se modification, 336
IP protection, 306, 349
limits of consent, 316
freedom as non-domination
definition, 44, 47, 50
free State, 47
republicanism, 8, 10

genetic resources, xvii, xx, 148–150, 191–193, 348–349

human rights
critical human rights approach, 200
duties of States, 131, 237, 245, 304
interface with IP, 121
as interpretative resources, 60, 68, 120–121, 124, 128–129, 198, 200, 357
responsibilities of companies, 164

ICESCR
access modality, 157, 168
interpretation, 120, 129, 135–138, 150, 153
ideal theory, 39, 41–42, 50, 60, 196, 354–356
India – Patents, xiv, 27
indigenous communities
self-determination, 14, 141, 152, 157, 182, 184, 188–201, 354, 358
inter se modification, 16, 333–336
interpretation, *See also VCLT*
constructivist, 25, 32
object and purpose, 8, 15, 25, 28–31, 36, 67, 113, 206, 209, 286, 293, 329

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 14 Nov 2026 at 09:40:10, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009743174.011

ordinary meaning, 29, 35, 83, 126, 209, 341
requirements of accountability, 25–27, 29, 36

justice, *see also freedom as non-domination, see also sufficientarianism*
justification of intellectual property, 88–89

least-developed countries, *see also Art. 67 technical assistance, see also Art. 66(2) technology transfer*

manufacturing capacity, 1, 232–233, 238–239, 244, 248–258
Marrakesh Treaty
human rights as objective, 286
mandatory exceptions, 212, 283, 288–289, 292, 296–298, 300, 303–304
two paradigms on disabilities, 295
MFN, 306–320, 346, 349–350
minimum standard, 73, 110, 124, 153, 302, 307

national autonomy, *see self-determination*, *see Article 8 TRIPS*
necessity test, *see Article 8 TRIPS*
non-domination, *see freedom as non-domination*
normal exploitation, *see Article 30 TRIPS*, *see three-step test*

object and purpose, *see interpretation*
obligations of the State, 137, 297
ordinary meaning, *see interpretation*

patentability, *see flexibilities*
Philip Morris v. *Uruguay*, xiii, 117, 315, 325
private companies
human rights responsibilities, 130, 145, 244, 250, 360
technology transfer responsibilities, 274–276
public domain, 87, 192–193, 217, 265, 302, 310, 320, 348–349
public health, *see also compulsory licences, see also Doha Declaration, see also Article 31bis TRIPS*

reflective equilibrium, *see also interpretation*
criticism, 26, 38, 354
methodology, 353–356
moral arguments, 29, 34
regime shifting, 16, 306, 321–327, 338
regulatory autonomy, *see freedom as non-domination*
republican freedom, *see freedom as non-domination*
responsibilities, *see human rights*
right to education, 150–153
right to food, 146–150
right to health, 142–146
right to science
as access right, 162
benefits of science, 140, 153, 162–164, 171, 177, 199, 202
capacity to do science, 171
competence to determine a science framework, 171
interface with IP, 158
responsibilities of companies, 164
right to self-determination
for indigenous communities, 189–190, 200
interface with IP, 186–188
principle and human right, 185
republican interpretation, 197

science, *see also right to science*
as a public good, 170–172
science framework, 14, 170–172, 199, 224, 231, 288, 297, 300, 351
seeds, 2–3, 13, 53, 139, 147–148, 163–164, 173, 191, 193
self-determination, *see right to self-determination*
social and economic welfare, *see Article 7 TRIPS*
societal objectives, *see also justification of intellectual property*

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 14 Nov 2026 at 09:40:10, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009743174.011

sufficientarianism, *see also capability approach*
  allocation of responsibilities, 132–133
  definition, 10, 52–53
  essential goods, 141
sui generis protection, 147, 196, 201

technical assistance, *see also Article 67 TRIPS*
  definition, 277–278
technological innovation, *see also Article 7 TRIPS*
technology transfer, *see also Article 66(2) TRIPS*
  definition, 264–265
theory of justice, 7, 10, 18, 26, 41, 43, 45
three-step test, *see also US – Section 110(5) Copyright*, *see also Canada – Patent Protection of Pharmaceutical Products*, *see also Article 30 TRIPS*, *see also Article 13 TRIPS*
  compatibility with Marrakesh Treaty, 289–291
  conditions, 218–219, 223, 225, 228
traditional knowledge, *see also right to self-determination*
  protection, 77, 148, 188, 191
  public domain, critique of, 191–193
  UNDRIP, 189–191
  WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge, xx, 149
TRIPS-plus norms, *see flexibilities*

US – Section 110(5), 221, 229–230
users' rights, 208, 210, 228, 298, 302, 304

VCLT, *see also reflective equilibrium, see also interpretation*
  Article 31, 25–26, 29, 70, 111–112, 125–126, 341
  Article 32, 126
  Article 41, 16, 123, 333–336
visual disabilities, *see* Marrakesh Treaty

waiver, xv, xix, 2, 136, 146, 207, 212, 237, 244–245, 248–249, 257, 261, 330
WIPO Copyright Treaty, xix, 213, 283, 289–291
WIPO GRATK Treaty, 194
WTO Agreements, 27–28, 111, 126

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 14 Nov 2026 at 09:40:10, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781009743174.011